| pubmed-article:2598183 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2598183 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:2598183 | lifeskim:mentions | umls-concept:C0022687 | lld:lifeskim |
| pubmed-article:2598183 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:2598183 | lifeskim:mentions | umls-concept:C1522405 | lld:lifeskim |
| pubmed-article:2598183 | lifeskim:mentions | umls-concept:C0205373 | lld:lifeskim |
| pubmed-article:2598183 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:2598183 | pubmed:dateCreated | 1990-1-30 | lld:pubmed |
| pubmed-article:2598183 | pubmed:abstractText | The adoptive immunotherapy of human cancer using lymphokine-activated killer (LAK) cells in combination with high-dose systemic recombinant interleukin-2 (rIL-2) has been associated with global changes in several hematological and immunological parameters while imposing profound toxicity on patients. We have evaluated an alternative LAK cell therapy utilizing low-dose systemic rIL-2 is also characterized by significant changes in immunological and hematological parameters, which are qualitatively similar to those induced by high-dose rIL-2. Low-dose systemic rIL-2, given by i.v. bolus, is cleared to baseline levels within 240 min of administration. The induction of lymphocytosis and eosinophilia, which has characterized other protocols, is also a feature of this protocol. In addition, low-dose systemic rIL-2/LAK cell immunotherapy results in increased peripheral blood mononuclear cell (PBMC) expression of T-cell activation markers such as OKIa, OKT10 and IL-2 receptor. PBMC sampled approximately 100 h after the final infusion of LAK cells demonstrated a statistically significant increase in their ability to kill natural killer (NK)-sensitive and NK-resistant cell lines such as K562 and Daudi compared to baseline values (P less than .05). These data suggest that rIL-2-based immunotherapy using low-dose rIL-2 is capable of inducing quantitative hematological and immunological changes while (in combination with LAK cells) retaining the ability to mediate tumor regression in vivo. | lld:pubmed |
| pubmed-article:2598183 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2598183 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2598183 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2598183 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2598183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2598183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2598183 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2598183 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2598183 | pubmed:issn | 0340-7004 | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:MannickJ AJA | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:RodrickM LML | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:EberleinT JTJ | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:SchoonD LDL | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:MassaroA FAF | lld:pubmed |
| pubmed-article:2598183 | pubmed:author | pubmed-author:JungS ESE | lld:pubmed |
| pubmed-article:2598183 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2598183 | pubmed:volume | 30 | lld:pubmed |
| pubmed-article:2598183 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2598183 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2598183 | pubmed:pagination | 145-50 | lld:pubmed |
| pubmed-article:2598183 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:meshHeading | pubmed-meshheading:2598183-... | lld:pubmed |
| pubmed-article:2598183 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2598183 | pubmed:articleTitle | Immunomodulatory effects of systemic low-dose recombinant interleukin-2 and lymphokine-activated killer cells in humans. | lld:pubmed |
| pubmed-article:2598183 | pubmed:affiliation | Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115. | lld:pubmed |
| pubmed-article:2598183 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2598183 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:2598183 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2598183 | lld:pubmed |
